\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\ \(73\)\
\-\ surgery\\ followed\\ by\\ radiation\\ therapy\ \(1\)\
\-\ enhancing\\,\\ relatively\\ homogeneous\\,\\ cerebellar\\ mass\\.\ \(0\)\
\-\ compression\\ of\\ 4th\\ ventricle\\ with\\ supratentorial\\ obstructive\\ hydrocephalus\\.\ \(0\)\
\-\ medulloblastoma\ \(30\)\
\-\ \\â\\€\\¢\\ pnet\ \(0\)\
\-\ \\â\\€\\¢\\ ependymoma\ \(8\)\
\-\ \\â\\€\\¢\\ metastatic\\ disease\ \(13\)\
\-\ 31\\ y\\.o\\.\\ woman\\ presents\\ with\\ diplopia\\ and\\ ataxia\\.\ \(1\)\
\-\ initial\\ clinical\\ diagnosis\\ was\\ ms\ \(0\)\
\-\ most\\ medulloblastomas\\ \\-\\ about\\ 60\\%\\,\\ present\\ during\\ the\\ first\\ two\\ decades\\.\\ \\ however\\,\\ as\\ in\\ this\\ case\\,\\ about\\ 1\\/3\\ of\\ patients\\ present\\ over\\ the\\ age\\ of\\ fifteen\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ about\\:\\ 0\\.26465254738466626\ \(0\)\
\-\ medulloblastomas\\:\\ 0\\.2611942914095272\ \(0\)\
\-\ fifteen\\:\\ 0\\.2438539200095634\ \(0\)\
\-\ supratentorial\\:\\ 0\\.200897914103832\ \(0\)\
\-\ decades\\:\\ 0\\.19981056715694323\ \(0\)\
\-\ pnet\\:\\ 0\\.189845909978329\ \(0\)\
\-\ diplopia\\:\\ 0\\.1848488215569715\ \(0\)\
\-\ medulloblastoma\\:\\ 0\\.18355754270386815\ \(0\)\
\-\ present\\:\\ 0\\.18139911172163958\ \(0\)\
\-\ ataxia\\:\\ 0\\.17163262991532083\ \(0\)\
\-\ ms\\:\\ 0\\.17163262991532083\ \(0\)\
\-\ obstructive\\:\\ 0\\.16437586481642752\ \(0\)\
\-\ 4th\\:\\ 0\\.16271845328025983\ \(0\)\
\-\ 31\\:\\ 0\\.15685456125121186\ \(0\)\
\-\ homogeneous\\:\\ 0\\.15606338103545983\ \(0\)\
\-\ ependymoma\\:\\ 0\\.14930563663973256\ \(0\)\
\-\ cerebellar\\:\\ 0\\.14464896098500457\ \(0\)\
\-\ hydrocephalus\\:\\ 0\\.14429073493340716\ \(0\)\
\-\ relatively\\:\\ 0\\.14393660298346708\ \(0\)\
\-\ 60\\:\\ 0\\.13220546960813848\ \(0\)\
\-\ ventricle\\:\\ 0\\.1301078578382647\ \(0\)\
\-\ compression\\:\\ 0\\.1294390647896852\ \(0\)\
\-\ available\\:\\ 0\\.11992425561871153\ \(0\)\
\-\ followed\\:\\ 0\\.11936158527229217\ \(0\)\
\-\ first\\:\\ 0\\.11928203142025415\ \(0\)\
\-\ initial\\:\\ 0\\.11857509106159228\ \(0\)\
\-\ radiation\\:\\ 0\\.11713361216476341\ \(0\)\
\-\ clinical\\:\\ 0\\.11202002818283968\ \(0\)\
\-\ during\\:\\ 0\\.11195723949195636\ \(0\)\
\-\ age\\:\\ 0\\.11096954763928642\ \(0\)\
\-\ enhancing\\:\\ 0\\.11072746665527279\ \(0\)\
\-\ two\\:\\ 0\\.10496768805106182\ \(0\)\
\-\ however\\:\\ 0\\.10461924508866197\ \(0\)\
\-\ of\\:\\ 0\\.103771456789793\ \(0\)\
\-\ therapy\\:\\ 0\\.10155813452569029\ \(0\)\
\-\ patients\\:\\ 0\\.0994352581614\ \(0\)\
\-\ over\\:\\ 0\\.09828444442166276\ \(0\)\
\-\ metastatic\\:\\ 0\\.09694215674421089\ \(0\)\
\-\ surgery\\:\\ 0\\.09503182788411721\ \(0\)\
\-\ woman\\:\\ 0\\.09205541877085728\ \(0\)\
\-\ most\\:\\ 0\\.09198949064311751\ \(0\)\
\-\ diagnosis\\:\\ 0\\.09162937217686275\ \(0\)\
\-\ case\\:\\ 0\\.08880059720984207\ \(0\)\
\-\ presents\\:\\ 0\\.08502905170152661\ \(0\)\
\-\ by\\:\\ 0\\.07506110668712507\ \(0\)\
\-\ disease\\:\\ 0\\.07419614422449569\ \(0\)\
\-\ as\\:\\ 0\\.07100940212662687\ \(0\)\
\-\ the\\:\\ 0\\.07053869556352038\ \(0\)\
\-\ not\\:\\ 0\\.06977930378165283\ \(0\)\
\-\ with\\:\\ 0\\.06922230680699835\ \(0\)\
\-\ mass\\:\\ 0\\.06751630525501989\ \(0\)\
\-\ was\\:\\ 0\\.06160142745617307\ \(0\)\
\-\ this\\:\\ 0\\.06073675323600164\ \(0\)\
\-\ in\\:\\ 0\\.043971307302600564\ \(0\)\
\-\ and\\:\\ 0\\.036524588780267576\ \(0\)\
